FDA Heeds Industry Concerns, Expands Racial Categories For Clinical Data Collection
Executive Summary
Updated US draft guidance for collecting ethnic and racial information on clinical trial subjects allows for more specific, geographic identification of subjects.
You may also be interested in...
US FDA Extends Race/Ethnicity Clinical Data Collection Guidelines To Observational Studies
However, new draft guidance expressly does not address diversity action plans required under Food and Drug Omnibus Reform Act; initial guidance on these plans was due in December 2023 but has yet to be released.
Xpovio Avoided Complete Response Letter Through Late-Cycle Submission Of BOSTON Data
After US FDA's Oncologic Drugs Advisory Committee voted to delay approval of Karyopharm's multiple myeloma drug Xpovio, the company submitted some data from the Phase III BOSTON trial, which prompted the FDA to award an accelerated approval for a narrower indication.
Xpovio Clinical Development Timeline
Chronicle of the development and review of Karyopharm's Xpovio (selinexor) for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies.